Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI J Med Econ. 2012 May 14. PMID: 22583065. Abstract CommentRecommendBookmarkWatch